Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Phase IV Multicentric Study, 140 Patients Suffering of Meibomian Glands Dysfunction.

Multicentric study, open label, uncontrolled phase IV in 140 patients with meibomian glands dysfunction .

Its objective is to Collect information from patients and ophthalmologists specialized in ocular surface and eyelids to anticipate how Blephasteam ® can be optimized.

This study involves 2 visits, visit of Inclusion, J0, then end of study visit, D21.

Between the two visits patients will be treated with Blephasteam ® for 21 days (up to two uses per day) and complete a questionnaire every two days during the first week and then once a week the next two weeks.

• Signed and dated informed consent.
• Male or female up to 4 years old.
• Known and treated symptomatic Meibomian Gland Diseases, and/or Dry Eye related to MGDs stable since at least a month.
• Without any active pathology requiring a change in ocular treatments within the last month before inclusion.
• Best corrected far visual acuity (VA) > 1/10